Hui, Rex Wan-Hin
Mak, Lung-Yi
Cheung, Ka-Shing
Fung, James
Seto, Wai-Kay
Yuen, Man-Fung https://orcid.org/0000-0001-7985-7725
Article History
Accepted: 22 September 2022
First Online: 6 October 2022
Declarations
:
: Rex Wan-Hin Wu, Lung-Yi Mak, Ka-Shing Cheung, and James Fung declare no conflict of interests.Man-Fung Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp, and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation, and Sysmex Corporation.Wai-Kay Seto received speaker’s fees from AstraZeneca and Mylan, is an advisory board member of CSL Behring, is an advisory board member and received speaker’s fees from AbbVie, and is an advisory board member, received speaker’s fees and researching funding from Gilead Sciences. The remaining authors have no conflict of interest.
: This paper does not involve human participants or animals.